BCM
HRTX icon

Bourgeon Capital Management’s Heron Therapeutics HRTX Stock Holding History

Bourgeon Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,000
Closed -$8K – 403
2022
Q2 		$8K Hold
3,000
– – ﹤0.01% 227
2022
Q1 		$17K Buy
+3,000
New +$22K ﹤0.01% 202

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bourgeon Capital Management's HRTX Position: Q3 2022 in Review

Bourgeon Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 3,000 shares — an estimated $8K sold.

Bourgeon Capital Management first reported a position in HRTX in Q1 2022 and held it in 2 quarters. The position peaked at $17K in Q1 2022. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

  • Bourgeon Capital Management reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bourgeon Capital Management sold 3,000 Heron Therapeutics shares in Q3 2022, an estimated $8K.
  • Bourgeon Capital Management first reported a position in Heron Therapeutics in Q1 2022 and held it in 2 quarters.
  • Bourgeon Capital Management's Heron Therapeutics position peaked at $17K in Q1 2022.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Bourgeon Capital Management's 13F filing for Q3 2022, filed 27 Oct 2022.